Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc. has entered into a settlement agreement with Orion Corporation to resolve patent litigation related to entacapone tablets, 200 mg. Entacapone tablets are the generic version of Orion's Comtan, indicated as an adjunct to levodopa/carbidopa therapy to treat patients with idiopathic Parkinson's disease (PD) who experience the signs and symptoms of end-of-dose "wearing-off".

Under the terms of the settlement agreement, Mylan may launch a generic version of Comtan, 200 mg, on April 1, 2013, at the earliest. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission.

Entacapone tablets, 200 mg, had US sales of approximately $104.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health.